Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of Georgia
6 affiliations
- 1Bristol Medical School, University of Bristol, Bristol, United Kingdom
- 2Task Force for Global Health, Tbilisi, Georgia
- 3Division of Viral Hepatitis, US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
- 4Ministry of Internally Displaced Persons from Occupied Territories, Health, Labour and Social Affairs, Tbilisi, Georgia
- 5AIDS & Clinical Immunology Research Center, Tbilisi, Georgia
- 6National Center for Disease Control and Public Health, Tbilisi, Georgia
Abstract
We evaluated the cost and cost-effectiveness of alternative screening pathways during 2018–2022 within Georgia’s hepatitis C elimination program, which started in 2015. We calculated patient-level costs (2022 USD$) of hepatitis C treatment with centralized and decentralized diagnostic testing in hospitals, primary healthcare (PHC), harm reduction providers (HRP), or specialized providers (SP) from reimbursement records including the value of donated direct-acting antivirals (DAAs). We model hepatitis C case-finding, transmission, and progression over a 20-year time horizon to project cost-effectiveness of treatment for each screening pathway in terms of cost per quality adjusted life year (QALY), compared to a willingness-to-pay threshold of $1,337. Unit costs of treatment decreased from 3942–4247 across screening pathways in 2018 to 300–338 in 2022, primarily due to reductions in DAA costs. The cascade of care varied by screening pathway, with highest hepatitis C virus (HCV) antibody prevalence and percent linked to viremia testing among HRP and SP, while total number of patients screened was highest in hospitals. While DAA costs decreased, the cost of case finding increased during 2018–2022, with the biggest increase in hospital settings mainly due to decreasing yield. The program was not cost-effective with full DAA costs, but excluding DAA costs or using lower 2022 costs make all pathways cost-effective and SP, HRP, and PHC potentially cost-saving. Donated drugs allowed Georgia’s HCV elimination program to be cost-effective, while future programs with generic drug costs are likely to be cost-effective. Reductions in yield from hospital screening suggest that later stages of elimination programs should prioritise targeted pathways.
Related
- Strategies and approaches to vector control effectiveness toward the elimination of malaria in mainland Tanzania: An implementation case study analysis
- Effectiveness of the PPR Sungri-96 Vaccine in Sheep and Goats in India: A Nationwide Post-Vaccination Seromonitoring Study Towards PPR Elimination.
- Comparing the cost-effectiveness of alternative policies for recommending and providing HIV pre-exposure prophylaxis to men who have sex with men in the EU
- A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer (eREACH2): study protocol
- Effectiveness of health mediation to promote organised cancer screening among underserved and under-screened populations in Marseille, France: findings from a repeated cross-sectional survey.
BibTeX
@article{walker2026cost,
title = {{Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of Georgia}},
author = {Josephine G. Walker and Irina Tskhomelidze Schumacher and Shaun Shadaker and Tamar Gabunia and Rania A. Tohme and Akaki Abutidze and Vladimer Getia and Peter Vickerman},
journal = {PLOS Global Public Health},
year = {2026},
month = sep,
doi = {10.1371/journal.pgph.0007122},
url = {https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0007122},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of Georgia
AU - Josephine G. Walker
AU - Irina Tskhomelidze Schumacher
AU - Shaun Shadaker
AU - Tamar Gabunia
AU - Rania A. Tohme
AU - Akaki Abutidze
AU - Vladimer Getia
AU - Peter Vickerman
PY - 2026
DA - 2026/09/22
JO - PLOS Global Public Health
DO - 10.1371/journal.pgph.0007122
UR - https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0007122
AB - We evaluated the cost and cost-effectiveness of alternative screening pathways during 2018–2022 within Georgia’s hepatitis C elimination program, which started in 2015. We calculated patient-level costs (2022 USD$) of hepatitis C treatment with centralized and decentralized diagnostic testing in hospitals, primary healthcare (PHC), harm reduction providers (HRP), or specialized providers (SP) from reimbursement records including the value of donated direct-acting antivirals (DAAs). We model hepatitis C case-finding, transmission, and progression over a 20-year time horizon to project cost-effectiveness of treatment for each screening pathway in terms of cost per quality adjusted life year (QALY), compared to a willingness-to-pay threshold of $1,337. Unit costs of treatment decreased from 3942–4247 across screening pathways in 2018 to 300–338 in 2022, primarily due to reductions in DAA costs. The cascade of care varied by screening pathway, with highest hepatitis C virus (HCV) antibody prevalence and percent linked to viremia testing among HRP and SP, while total number of patients screened was highest in hospitals. While DAA costs decreased, the cost of case finding increased during 2018–2022, with the biggest increase in hospital settings mainly due to decreasing yield. The program was not cost-effective with full DAA costs, but excluding DAA costs or using lower 2022 costs make all pathways cost-effective and SP, HRP, and PHC potentially cost-saving. Donated drugs allowed Georgia’s HCV elimination program to be cost-effective, while future programs with generic drug costs are likely to be cost-effective. Reductions in yield from hospital screening suggest that later stages of elimination programs should prioritise targeted pathways.
SN - 2767-3375
ER -